Reference : A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.
Scientific journals : Article
Human health sciences : Neurology
Systems Biomedicine
http://hdl.handle.net/10993/51603
A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.
English
Campbell, Ciarán [> >]
McCormack, Mark [> >]
Patel, Sonn [> >]
Stapleton, Caragh [> >]
Bobbili, Dheeraj Reddy mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core]
Krause, Roland mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Bioinformatics Core]
Depondt, Chantal [> >]
Sills, Graeme J. [> >]
Koeleman, Bobby P. [> >]
Striano, Pasquale [> >]
Zara, Federico [> >]
Sander, Josemir W. [> >]
Lerche, Holger [> >]
Kunz, Wolfram S. [> >]
Stefansson, Kari [> >]
Stefansson, Hreinn [> >]
Doherty, Colin P. [> >]
Heinzen, Erin L. [> >]
Scheffer, Ingrid E. [> >]
Goldstein, David B. [> >]
O'Brien, Terence [> >]
Cotter, David [> >]
Berkovic, Samuel F. [> >]
Sisodiya, Sanjay M. [> >]
Delanty, Norman [> >]
Cavalleri, Gianpiero L. [> >]
2022
Epilepsia
63
6
1563-1570
Yes (verified by ORBilu)
International
0013-9580
1528-1167
United States
[en] Anticonvulsants/adverse effects ; Case-Control Studies ; Drug-Related Side Effects and Adverse Reactions ; Genetic Predisposition to Disease/genetics ; Genome-Wide Association Study ; Humans ; Levetiracetam/adverse effects ; Pharmacogenetics ; Prospective Studies ; adverse drug reactions ; levetiracetam ; pharmacogenomics ; polygenic risk scoring ; psychosis
[en] OBJECTIVE: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%-20% of people treated with LEV report psychiatric side-effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine the contribution of both common and rare genetic variation to psychiatric and behavioral ADRs associated with LEV. METHODS: This case-control study compared cases of LEV-associated behavioral disorder (n = 149) or psychotic reaction (n = 37) to LEV-exposed people with no history of psychiatric ADRs (n = 920). All samples were of European ancestry. We performed genome-wide association study (GWAS) analysis comparing those with LEV ADRs to controls. We estimated the polygenic risk scores (PRS) for schizophrenia and compared cases with LEV-associated psychotic reaction to controls. Rare variant burden analysis was performed using exome sequence data of cases with psychotic reactions (n = 18) and controls (n = 122). RESULTS: Univariate GWAS found no significant associations with either LEV-associated behavioural disorder or LEV-psychotic reaction. PRS analysis showed that cases of LEV-associated psychotic reaction had an increased PRS for schizophrenia relative to contr ols (p = .0097, estimate = .4886). The rare-variant analysis found no evidence of an increased burden of rare genetic variants in people who had experienced LEV-associated psychotic reaction relative to controls. SIGNIFICANCE: The polygenic burden for schizophrenia is a risk factor for LEV-associated psychotic reaction. To assess the clinical utility of PRS as a predictor, it should be tested in an independent and ideally prospective cohort. Larger sample sizes are required for the identification of significant univariate common genetic signals or rare genetic signals associated with psychiatric LEV ADRs.
Researchers ; Professionals
http://hdl.handle.net/10993/51603
10.1111/epi.17228
© 2021 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
FP7 ; 279062 - EPIPGX - Epilepsy Pharmacogenomics: delivering biomarkers for clinical use

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Epilepsia - 2022 - Campbell - A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.pdfPublisher postprint1.12 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.